Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CRVO
stocks logo

CRVO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
983.33K
-54.52%
-0.644
-19.46%
275.00K
-85.66%
-0.608
+8.48%
350.00K
-80.09%
-0.502
-28.21%
Estimates Revision
The market is revising Downward the revenue expectations for CervoMed Inc. (CRVO) for FY2025, with the revenue forecasts being adjusted by -22.4% over the past three months. During the same period, the stock price has changed by -13.80%.
Revenue Estimates for FY2025
Revise Downward
down Image
-22.4%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+12.49%
In Past 3 Month
Stock Price
Go Down
down Image
-13.80%
In Past 3 Month
Wall Street analysts forecast CRVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVO is 22.75 USD with a low forecast of 19.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CRVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVO is 22.75 USD with a low forecast of 19.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.060
sliders
Low
19.00
Averages
22.75
High
27.00
Current: 9.060
sliders
Low
19.00
Averages
22.75
High
27.00
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$20 -> $19
2025-11-10
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$20 -> $19
2025-11-10
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on CervoMed to $19 from $20 and keeps a Buy rating on the shares. In the wake of Q3 financial results, the firm caught up with CervoMed CFO Bill Elder for further insights, the analyst tells investors in a research note. At the end of Q3 the company has roughly $27.3M in cash, which, per management's view, is expected to fund operations through 3Q26, the analyst notes.
H.C. Wainwright
Raghuram Selvaraju
Neutral -> Buy
upgrade
$25
2025-11-05
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$25
2025-11-05
upgrade
Neutral -> Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju upgraded CervoMed to Buy from Neutral with a $25 price target after the company received written feedback from the FDA aligning on key aspects of its proposed Phase 3 clinical trial of neflamapimod. The parameters on which CervoMed has reached alignment with the FDA "appear eminently logical and reasonable," the analyst tells investors in a research note. H.C. Wainwright believes this a "significant risk-mitigating development" for the company.
Roth Capital
Buy
upgrade
$16 -> $20
2025-10-17
Reason
Roth Capital
Price Target
$16 -> $20
2025-10-17
upgrade
Buy
Reason
Roth Capital raised the firm's price target on CervoMed to $20 from $16 and keeps a Buy rating on the shares. Following a re-analysis of the Phase 2b results, Roth is "convinced" that CervoMed's neflamapimod has the potential to become a new therapy for dementia with Lewy bodies. The firm increased the drug's probability of success to 50% from 40%, prompting the higher price target.
H.C. Wainwright
H.C. Wainwright
Neutral
maintain
$11
2025-09-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$11
2025-09-08
maintain
Neutral
Reason
H.C. Wainwright set a price target of $11 for CervoMed shares while keeping a Neutral rating on the name. The regulatory outlook for neflamapimod should be clarified in the near-term, the analyst tells investors in a research note. The firm says CervoMed is actively preparing for discussions with the FDA, which management expects to take place during Q4.
D. Boral Capital
Jason Kolbert
Buy
upgrade
$15 -> $31
2025-08-18
Reason
D. Boral Capital
Jason Kolbert
Price Target
$15 -> $31
2025-08-18
upgrade
Buy
Reason
D. Boral Capital analyst Jason Kolbert raised the firm's price target on CervoMed to $31 from $15 and keeps a Buy rating on the shares. The firm increased its probability of clinical success for neflamapimod in dementia with Lewy bodies to 30% from 15% based on recently presented data. The recent results "materially strengthen" the late-stage outlook for the program and address uncertainties, the analyst tells investors in a research note. D. Boral points out that the underdosed patients performed like placebo, while fully dosed patients drove the efficacy signal.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$20 -> $16
2025-08-12
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$20 -> $16
2025-08-12
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on CervoMed to $16 from $20 and keeps a Buy rating on the shares after its Q2 results. Following positive Week 32 Phase 2b OLE data, CervoMed is slated to meet with the FDA in Q4 to discuss the results generated to date and obtain guidance on its Phase 3 study preparations, the analyst tells investors in a research note. Roth has also updated its model that assumes $78M in equity financing, the firm added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for CervoMed Inc (CRVO.O) is -3.89, compared to its 5-year average forward P/E of -5.77. For a more detailed relative valuation and DCF analysis to assess CervoMed Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.77
Current PE
-3.89
Overvalued PE
-2.24
Undervalued PE
-9.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.19
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.13
Undervalued EV/EBITDA
-6.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
16.83
Current PS
0.00
Overvalued PS
27.08
Undervalued PS
6.58
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CRVO News & Events

Events Timeline

(ET)
2025-12-04
17:10:00
CervoMed Reports Positive Results from Alzheimer's Clinical Trial
select
2025-12-02 (ET)
2025-12-02
07:10:00
CervoMed Reports Significant Reduction in Neurodegeneration Biomarker from Phase 2b RewinD-LB Trial
select
2025-11-10 (ET)
2025-11-10
07:05:36
CervoMed Announces Q3 Earnings Per Share of 84 Cents, Exceeding Consensus Estimate of 56 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
06:21 AMGlobenewswire
CervoMed's Neflamapimod Shows Significant Improvement in DLB Patients in Phase 2b Trial
  • Clinical Trial Results: CervoMed's Phase 2b RewinD-LB trial demonstrated that neflamapimod significantly improved CDR-SB scores in DLB patients, achieving a 52% reduction compared to placebo over 16 weeks, indicating its potential as a treatment.
  • Biomarker Improvement: The treatment group showed a significant reduction in GFAP levels, suggesting that neflamapimod effectively targets neurodegenerative processes, reinforcing its scientific basis as a potential DLB therapy.
  • Future Trial Plans: CervoMed is set to initiate a global Phase 3 registrational trial in the second half of 2026 to further validate neflamapimod's efficacy, advancing its path to market.
  • Funding Support: The RewinD-LB trial received $21.3 million in NIH funding, covering 43 research sites across the U.S., U.K., and Netherlands, highlighting the broad support and potential impact of this research.
[object Object]
Preview
9.0
12-02Globenewswire
CervoMed Reports New Data on Neflamapimod Clinical Trial, Significant GFAP Reduction
  • Significant Biomarker Improvement: At the CTAD conference, CervoMed presented data showing that neflamapimod treatment led to a significant reduction in plasma GFAP levels, achieving a median of -16.0 pg/mL (p<0.0001), indicating the drug's potential in improving neurodegenerative conditions and offering new hope for DLB patients.
  • Clinical Effect Correlation: The study revealed a positive correlation between neflamapimod treatment and improvement in CDR-SB scores (r=0.35, p=0.036), which not only validates GFAP as an effective biomarker for DLB disease activity but also strengthens the conclusions regarding neflamapimod's clinical effects.
  • Successful Extension Phase: During the 32-week extension phase, patients receiving the new drug batch showed significant reductions in GFAP levels and a notable increase in the A42/40 ratio (p<0.001), suggesting that neflamapimod may act on the underlying disease process in DLB, enhancing the company's confidence as it moves towards the next phase of clinical trials.
  • Funding and Research Scale: The RewinD-LB trial was supported by a $21.3 million grant from the NIH, covering 43 research sites across the U.S., U.K., and Netherlands, demonstrating CervoMed's extensive research foundation and future growth potential in the neurodegenerative disease field.
[object Object]
Preview
9.0
12-02Newsfilter
CervoMed's Neflamapimod Significantly Reduces Neurodegeneration Biomarker GFAP
  • Clinical Trial Results: CervoMed presented Phase 2b trial results at the CTAD conference showing that neflamapimod significantly reduced plasma GFAP levels, indicating its potential efficacy in neurodegenerative diseases and offering a new treatment option for DLB patients.
  • Biomarker Correlation: The study found a positive correlation between the reduction in GFAP levels and clinical improvement (CDR-SB scores), further validating GFAP as an effective biomarker of disease activity in DLB and enhancing confidence in neflamapimod's clinical effects.
  • Treatment Continuity: During the 32-week extension, patients receiving the new drug batch showed a median GFAP reduction of 16.0 pg/mL and a significant increase in the Aβ42/40 ratio, demonstrating neflamapimod's potential to improve neuroinflammatory and neurodegenerative profiles.
  • Future Development Plans: CervoMed plans to initiate a global Phase 3 clinical trial in the second half of 2026 to further evaluate neflamapimod's efficacy in DLB patients, marking a strategic advancement in the treatment of neurodegenerative diseases.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CervoMed Inc (CRVO) stock price today?

The current price of CRVO is 9.06 USD — it has increased 9.42 % in the last trading day.

arrow icon

What is CervoMed Inc (CRVO)'s business?

CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

arrow icon

What is the price predicton of CRVO Stock?

Wall Street analysts forecast CRVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVO is 22.75 USD with a low forecast of 19.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CervoMed Inc (CRVO)'s revenue for the last quarter?

CervoMed Inc revenue for the last quarter amounts to 322.57K USD, decreased -83.37 % YoY.

arrow icon

What is CervoMed Inc (CRVO)'s earnings per share (EPS) for the last quarter?

CervoMed Inc. EPS for the last quarter amounts to -0.84 USD, increased 52.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for CervoMed Inc (CRVO)'s fundamentals?

The market is revising Downward the revenue expectations for CervoMed Inc. (CRVO) for FY2025, with the revenue forecasts being adjusted by -22.4% over the past three months. During the same period, the stock price has changed by -13.80%.
arrow icon

How many employees does CervoMed Inc (CRVO). have?

CervoMed Inc (CRVO) has 15 emplpoyees as of December 05 2025.

arrow icon

What is CervoMed Inc (CRVO) market cap?

Today CRVO has the market capitalization of 81.98M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free